The efficacy of BTKi-BCL2i combinations are reported in short follow-up of phase II studies only, however demonstrate impressive CR and uMRD rates in TP53 aberrant CLL. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.